Tags

Type your tag names separated by a space and hit enter

Design and evaluation of novel barrier layer technologies for controlling venlafaxine hydrochloride release from tablet dosage form.
Pharm Dev Technol. 2015; 20(5):588-97.PD

Abstract

CONTEXT

Venlafaxine Hydrochloride (VH) is a highly soluble and highly permeable antidepressant compound. Thus controlling VH release from tablet dosage form over a prolonged period is a challenge.

OBJECTIVE

The objective of this work was to study the effect of various barrier layer formulation compositions, its orientations and manufacturing technology on release profile of highly soluble VH.

MATERIALS AND METHODS

Different barrier compositions and orientations were established on the same extended release formulations of VH using compression as well as film coating technologies. Barrier effectiveness in reducing the VH release was verified through in vitro dissolution studies.

RESULTS AND DISCUSSION

The "belly band" portion of the tablets was successfully oriented in different ways to develop bilayer as well as trilayer tablets. The compression technology had substantially reduced the VH release up to 16% in various compositions and orientation as compared to core tablet. The film coating technology had reduced the VH release up to 14% effectively; thereby shifting the dissolution curve to downside.

CONCLUSION

The explored "belly band" portion of the tablets had reduced the VH release substantially. These innovatively created different barrier orientation technologies hold the great promise of commercialization in future.

Authors+Show Affiliations

Lupin Ltd. (Research Park) , Nande Village, Mulshi Taluka, Pune, Mahrarashtra , India and.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

24754412

Citation

Malewar, Nikhil, et al. "Design and Evaluation of Novel Barrier Layer Technologies for Controlling Venlafaxine Hydrochloride Release From Tablet Dosage Form." Pharmaceutical Development and Technology, vol. 20, no. 5, 2015, pp. 588-97.
Malewar N, Avachat M, Kulkarni S, et al. Design and evaluation of novel barrier layer technologies for controlling venlafaxine hydrochloride release from tablet dosage form. Pharm Dev Technol. 2015;20(5):588-97.
Malewar, N., Avachat, M., Kulkarni, S., & Pokharkar, V. (2015). Design and evaluation of novel barrier layer technologies for controlling venlafaxine hydrochloride release from tablet dosage form. Pharmaceutical Development and Technology, 20(5), 588-97. https://doi.org/10.3109/10837450.2014.908303
Malewar N, et al. Design and Evaluation of Novel Barrier Layer Technologies for Controlling Venlafaxine Hydrochloride Release From Tablet Dosage Form. Pharm Dev Technol. 2015;20(5):588-97. PubMed PMID: 24754412.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Design and evaluation of novel barrier layer technologies for controlling venlafaxine hydrochloride release from tablet dosage form. AU - Malewar,Nikhil, AU - Avachat,Makarand, AU - Kulkarni,Shirish, AU - Pokharkar,Varsha, Y1 - 2014/04/23/ PY - 2014/4/24/entrez PY - 2014/4/24/pubmed PY - 2016/4/22/medline KW - Barriers KW - belly band KW - controlled release KW - dissolution profile KW - highly soluble KW - rapid release KW - technology KW - venlafaxine hydrochloride SP - 588 EP - 97 JF - Pharmaceutical development and technology JO - Pharm Dev Technol VL - 20 IS - 5 N2 - CONTEXT: Venlafaxine Hydrochloride (VH) is a highly soluble and highly permeable antidepressant compound. Thus controlling VH release from tablet dosage form over a prolonged period is a challenge. OBJECTIVE: The objective of this work was to study the effect of various barrier layer formulation compositions, its orientations and manufacturing technology on release profile of highly soluble VH. MATERIALS AND METHODS: Different barrier compositions and orientations were established on the same extended release formulations of VH using compression as well as film coating technologies. Barrier effectiveness in reducing the VH release was verified through in vitro dissolution studies. RESULTS AND DISCUSSION: The "belly band" portion of the tablets was successfully oriented in different ways to develop bilayer as well as trilayer tablets. The compression technology had substantially reduced the VH release up to 16% in various compositions and orientation as compared to core tablet. The film coating technology had reduced the VH release up to 14% effectively; thereby shifting the dissolution curve to downside. CONCLUSION: The explored "belly band" portion of the tablets had reduced the VH release substantially. These innovatively created different barrier orientation technologies hold the great promise of commercialization in future. SN - 1097-9867 UR - https://www.unboundmedicine.com/medline/citation/24754412/Design_and_evaluation_of_novel_barrier_layer_technologies_for_controlling_venlafaxine_hydrochloride_release_from_tablet_dosage_form_ L2 - https://www.tandfonline.com/doi/full/10.3109/10837450.2014.908303 DB - PRIME DP - Unbound Medicine ER -